Jamshidi N, Taylor D A
Department of Pharmaceutical Biology and Pharmacology, Victorian College of Pharmacy, Monash University, 381 Royal Parade, Parkville 3052, Victoria, Australia.
Br J Pharmacol. 2001 Nov;134(6):1151-4. doi: 10.1038/sj.bjp.0704379.
This investigation reports the possible role of the endocannabinoid anandamide in modulating appetitive behaviour. Given that cannabinoids have been used clinically to stimulate appetite in HIV and cancer chemotherapy patients, there has been a renewed interest in the involvement of cannabinoids in appetite modulation. This is the first report on the administration of anandamide into the ventromedial hypothalamus. Pre-satiated rats received an intrahypothalamic injection of anandamide (50 ng x 0.5 microl(-1)) followed by measurement of food intake at 3 h post injection. Administration of anandamide induced significant hyperphagia. Pretreatment with the selective CB1 cannabinoid antagonist SR 141716 (30 microg x 0.5 microl(-1)), 30 min prior to anandamide injection resulted in an attenuation of the anandamide-induced hyperphagia (P<0.001). This study demonstrates that intrahypothalamic anandamide initiates appetite by stimulation of CB1 receptors, thus providing evidence on the involvement of hypothalamic endocannabinoids in appetite initiation.
本研究报告了内源性大麻素花生四烯乙醇胺在调节食欲行为中可能发挥的作用。鉴于大麻素已在临床上用于刺激艾滋病病毒感染者和癌症化疗患者的食欲,人们对大麻素参与食欲调节的兴趣再度燃起。这是关于向腹内侧下丘脑注射花生四烯乙醇胺的首份报告。给处于预饱状态的大鼠进行下丘脑内注射花生四烯乙醇胺(50纳克×0.5微升⁻¹),随后在注射后3小时测量食物摄入量。注射花生四烯乙醇胺会引发显著的摄食过量。在注射花生四烯乙醇胺前30分钟,用选择性CB1大麻素拮抗剂SR 141716(30微克×0.5微升⁻¹)进行预处理,可使花生四烯乙醇胺诱导的摄食过量减弱(P<0.001)。本研究表明,下丘脑内的花生四烯乙醇胺通过刺激CB1受体引发食欲,从而为下丘脑内源性大麻素参与食欲启动提供了证据。